Wednesday, July 8, 2026

biotech · Chronic Hepatitis b · Hepatitis B, Chronic · ABUS

Arbutus Biopharma

Arbutus Biopharma is a biotech organization headquartered in Warminster, USA. It trades on NYSE under ticker ABUS. Primary therapeutic focus areas include Chronic Hepatitis b, Hepatitis B, Chronic, Ebola Virus Infection,

701 Veterans Circle, Warminster, Pennsylvania 18974, US HQ
49 Employees
Public company Type
ABUS · NYSE Ticker
Company details
Status
Public
HQ
701 Veterans Circle, Warminster, Pennsylvania 18974, US
Employees
49
Programs
13
Drugs
7
Patents
56
Clinical program

AB-836

Phase 1 · small molecule · Chronic Hepatitis

AB-836 for Chronic Hepatitis is a Phase 1 program (small_molecule) at Arbutus Biopharma Corp with 1 ClinicalTrials.gov record(s).

← All Arbutus Biopharma Corp projects Phase 1 small molecule terminated

Internal code AB-836-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Arbutus Biopharma Corp
Phase
Phase 1
Modality
small_molecule
Indication
Chronic Hepatitis
Status
terminated
Trials
1

Clinical trials